Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Catanzaro, Antonino ^a   Rodwell, Timothy C ^a   Catanzaro, Donald G ^b   Garfein, Richard S ^a   Jackson, Roberta L ^a   Seifert, Marva ^a   Georghiou, Sophia B ^a   Trollip, Andre ^c   Groessl, Erik ^a   Hillery, Naomi ^a   Crudu, Valeriu ^d   Victor, Thomas C ^c   Rodrigues, Camilla ^e   Lin, Grace Shou Yean ^f   Valafar, Faramarz ^g   Desmond, Edward ^f   Eisenach, Kathleen ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARKANSAS   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Microbiology and Morphology Laboratory   (Moldova)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^g SAN DIEGO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; INDIA; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC OBSERVATION OF DRUG SUSCEPTIBILITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM; NONHUMAN; PYROSEQUENCING; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS RAPID TEST; VERY ELDERLY; ADOLESCENT; ADULT; CLINICAL TRIAL; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MOLDOVA; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84943257313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136861     Document Type: Article

References (37)

1. WHO. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization, 2014 2014. Report No.
2. Institute of Medicine (US). Ending Neglect: The Elimination of Tuberculosis in the United States. Geiter L, editor. Washington (DC): National Academy Press (US); 2000.
3. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PloSone. 2010;5(12):e15735. Epub 2011/01/07. doi: 10.1371/journal.pone.0015735 PMID: 21209951
4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine. 2003;167(4):603-62. PMID: 12588714
5. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010;14(10):1233-43.
6. Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(9):1019-25.
7. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, et al. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): Design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials. 2014; Manuscript accepted for publication.
8. Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol. 2014;52(2):475-82. Epub 2014/01/31. doi: 10.1128/JCM.01821-13 PMID: 24478476
9. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, et al. Predicting extensively drugresistant Mycobacterium tuberculosis phenotypes with genetic mutations. Journal of clinical microbiology. 2014;52(3):781-9. Epub 2013/12/20. doi: 10.1128/JCM.02701-13 PMID: 24353002
10. Trollip AP, Moore D, Coronel J, Caviedes L, Klages S, Victor T, et al. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(2):227-32. Epub 2014/01/17.
11. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. The European respiratory journal. 2008;32(5):1165-74. Epub 2008/07/11. doi: 10.1183/09031936.00061808 PMID: 18614561
12. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. Journal of clinical microbiology. 2012;50(11):3712-6. Epub 2012/09/14. doi: 10.1128/JCM.01958-12 PMID: 22972826
13. WHO. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 2008.
14. WHO. WHO policy statement: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. Geneva, Switzerland: World Health Organization, 2013.
15. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. Journal of clinical microbiology. 2006;44(6):1925-9. PMID: 16757581
16. Marttila HJ, Makinen J, Marjamaki M, Soini H. Prospective evaluation of pyrosequencing forthe rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2009;28(1):33-8.
17. Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, et al. Evaluation of Pyrosequencing for Detecting Extensively Drug-resistant Tuberculosis (XDR-TB) in Clinical Isolates from Four High-burden Countries. Antimicrob Agents Chemother. 2015. Epub 3 November 2014.
18. Engstrom A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. Journal of clinical microbiology. 2012;50(6):2026-33. Epub 2012/03/31. doi: 10.1128/JCM.06664-11 PMID: 22461677
19. Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. Journal of clinical microbiology. 2000;38(3):1203-8. PMID: 10699023
20. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drugsusceptibility assay for the diagnosis of TB. The New England journal of medicine. 2006;355(15):1539-50. PMID: 17035648
21. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. The New England journal of medicine. 2010;363(11):1005-15. doi: 10.1056/NEJMoa0907847 PMID: 20825313
22. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clinical chemistry. 2003;49(1):1-6. PMID: 12507953
23. Kent PT, Kubica GP, Centers for Disease Control (U. S.). Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Ga.: U. S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control; 1985. viii, 207 p. p.
24. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2008;12(12):1449-55.
25. WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva, Switzerland: World Health Organization, 2008.
26. Lifescience H. GenoType MTBDRslver 1.0: instruction manual. Nehren, Germany: Hain Lifescience GmbH, 2009.
27. Lifescience H. GenoType MTBDRplus ver 2.0: instruction manual. Nehren, Germany: Hain Lifescience GmbH, 2012.
28. Bravo LT, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. Journal of clinical microbiology. 2009;47(12):3985-90. doi: 10.1128/JCM.01229-09 PMID: 19846642
29. Park WG, Bishai WR, Chaisson RE, Dorman SE. Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. Journal of clinical microbiology. 2002;40(12):4750-2. PMID: 12454186
30. Ilstrup DM. Statistical methods in microbiology. Clin Microbiol Rev. 1990;3:219-26. PMID: 2200604
31. Dixit P, Singh U, Sharma P, Jain A. Evaluation of nitrate reduction assay, resazurin microtiter assay and microscopic observation drug susceptibility assay for first line antitubercular drug susceptibility testing of clinical isolates of M. tuberculosis. Journal of microbiological methods. 2012;88(1):122-6. doi: 10.1016/j.mimet.2011.11.006 PMID: 22133919
32. WHO. Expert Group Report: Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multi-drug Resistant Tuberculosis. 2008.
33. Huang Z, Li G, Chen J, Li W, Xu X, Luo Q, et al. Evaluation of MODS assay for rapid detection of Mycobacterium tuberculosis resistance to second-line drugs in a tertiary care tuberculosis hospital in China. Tuberculosis. 2014;94(5):506-10. doi: 10.1016/j.tube.2014.06.005 PMID: 25082461
34. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, et al. Diagnostic Performance of the new version of GenoType MTBDRsl (V2.0) Assay for detection of resistance to Fluoroquinolones and Second Line Injectable Drugs: aMulticenterstudy. Journal of Clinical Microbiology. 2015; doi: 10.1128/JCM.01257-15
35. Huang ZK, Luo Q, Xiong GL, Li WT, Xu XM, Li JM. Evaluation of indirect drug susceptibility testing using the MODS assay for the detection of XDR-TB in China. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(4):461-5.
36. Martin L, Coronel J, Faulx D, Valdez M, Metzler M, Crudder C, et al. A field evaluation of the Hardy TB MODS Kit for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis. PloS one. 2014;9(9):e107258. doi: 10.1371/journal.pone.0107258 PMID: 25225802
37. Makamure B, Mhaka J, Makumbirofa S, Mutetwa R, Mupfumi L, Mason P, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, Zimbabwe. PloS one. 2013;8(2):e5587